These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 36749880)
1. Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report. Pinto N; Naranjo A; Ding X; Zhang FF; Hibbitts E; Kennedy R; Tibbetts R; Wong-Michalak S; Craig DW; Manojlovic Z; Hogarty MD; Kreissman S; Bagatell R; Irwin MS; Park JR; Asgharzadeh S Clin Cancer Res; 2023 Apr; 29(8):1546-1556. PubMed ID: 36749880 [TBL] [Abstract][Full Text] [Related]
2. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable Ambros IM; Tonini GP; Pötschger U; Gross N; Mosseri V; Beiske K; Berbegall AP; Bénard J; Bown N; Caron H; Combaret V; Couturier J; Defferrari R; Delattre O; Jeison M; Kogner P; Lunec J; Marques B; Martinsson T; Mazzocco K; Noguera R; Schleiermacher G; Valent A; Van Roy N; Villamon E; Janousek D; Pribill I; Glogova E; Attiyeh EF; Hogarty MD; Monclair TF; Holmes K; Valteau-Couanet D; Castel V; Tweddle DA; Park JR; Cohn S; Ladenstein R; Beck-Popovic M; De Bernardi B; Michon J; Pearson ADJ; Ambros PF J Clin Oncol; 2020 Nov; 38(31):3685-3697. PubMed ID: 32903140 [TBL] [Abstract][Full Text] [Related]
3. Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). Pinto N; Naranjo A; Hibbitts E; Kreissman SG; Granger MM; Irwin MS; Bagatell R; London WB; Greengard EG; Park JR; DuBois SG Eur J Cancer; 2019 May; 112():66-79. PubMed ID: 30947024 [TBL] [Abstract][Full Text] [Related]
4. Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification. Bender HG; Irwin MS; Hogarty MD; Castleberry R; Maris JM; Kao PC; Zhang FF; Naranjo A; Cohn SL; London WB J Clin Oncol; 2023 Jun; 41(17):3149-3159. PubMed ID: 37098238 [TBL] [Abstract][Full Text] [Related]
5. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743 [TBL] [Abstract][Full Text] [Related]
6. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206 [TBL] [Abstract][Full Text] [Related]
7. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. Kawano A; Hazard FK; Chiu B; Naranjo A; LaBarre B; London WB; Hogarty MD; Cohn SL; Maris JM; Park JR; Gastier-Foster JM; Ikegaki N; Shimada H Am J Surg Pathol; 2021 Aug; 45(8):1075-1081. PubMed ID: 33739795 [TBL] [Abstract][Full Text] [Related]
8. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. Irwin MS; Naranjo A; Zhang FF; Cohn SL; London WB; Gastier-Foster JM; Ramirez NC; Pfau R; Reshmi S; Wagner E; Nuchtern J; Asgharzadeh S; Shimada H; Maris JM; Bagatell R; Park JR; Hogarty MD J Clin Oncol; 2021 Oct; 39(29):3229-3241. PubMed ID: 34319759 [TBL] [Abstract][Full Text] [Related]
9. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. Twist CJ; Naranjo A; Schmidt ML; Tenney SC; Cohn SL; Meany HJ; Mattei P; Adkins ES; Shimada H; London WB; Park JR; Matthay KK; Maris JM J Clin Oncol; 2019 Jan; 37(2):115-124. PubMed ID: 30444686 [TBL] [Abstract][Full Text] [Related]
10. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. Simon T; Spitz R; Faldum A; Hero B; Berthold F J Pediatr Hematol Oncol; 2004 Dec; 26(12):791-6. PubMed ID: 15591897 [TBL] [Abstract][Full Text] [Related]
11. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group. Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000 [TBL] [Abstract][Full Text] [Related]
12. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Campbell K; Gastier-Foster JM; Mann M; Naranjo AH; Van Ryn C; Bagatell R; Matthay KK; London WB; Irwin MS; Shimada H; Granger MM; Hogarty MD; Park JR; DuBois SG Cancer; 2017 Nov; 123(21):4224-4235. PubMed ID: 28696504 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664 [TBL] [Abstract][Full Text] [Related]
14. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154 [TBL] [Abstract][Full Text] [Related]
15. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. Bagatell R; Beck-Popovic M; London WB; Zhang Y; Pearson AD; Matthay KK; Monclair T; Ambros PF; Cohn SL; J Clin Oncol; 2009 Jan; 27(3):365-70. PubMed ID: 19047282 [TBL] [Abstract][Full Text] [Related]
16. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients. Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155 [TBL] [Abstract][Full Text] [Related]
17. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index. Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714 [TBL] [Abstract][Full Text] [Related]
18. Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era. Kushner BH; Modak S; Kramer K; LaQuaglia MP; Yataghene K; Basu EM; Roberts SS; Cheung NK Cancer; 2014 Jul; 120(13):2050-9. PubMed ID: 24691684 [TBL] [Abstract][Full Text] [Related]
19. Event-free survival in neuroblastoma with MYCN amplification and deletion of 1p or 11q may be associated with altered immune status. Wei Z; Gong B; Li X; Chen C; Zhao Q BMC Cancer; 2024 Oct; 24(1):1279. PubMed ID: 39407175 [TBL] [Abstract][Full Text] [Related]
20. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. Spitz R; Hero B; Ernestus K; Berthold F Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]